241 related articles for article (PubMed ID: 35983661)
21. The odyssey of pacritinib in myelofibrosis.
Venugopal S; Mascarenhas J
Blood Adv; 2022 Aug; 6(16):4905-4913. PubMed ID: 35622972
[TBL] [Abstract][Full Text] [Related]
22. An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis.
Saleh K; Ribrag V
Expert Rev Hematol; 2023 Apr; 16(4):227-236. PubMed ID: 36939633
[TBL] [Abstract][Full Text] [Related]
23. Managing side effects of JAK inhibitors for myelofibrosis in clinical practice.
Saeed I; McLornan D; Harrison CN
Expert Rev Hematol; 2017 Jul; 10(7):617-625. PubMed ID: 28571503
[TBL] [Abstract][Full Text] [Related]
24. Managing patients with myelofibrosis and thrombocytopenia.
Yilmaz M; Verstovsek S
Expert Rev Hematol; 2022 Mar; 15(3):233-241. PubMed ID: 35316110
[TBL] [Abstract][Full Text] [Related]
25. Safety considerations when treating myelofibrosis.
O'Sullivan JM; McLornan DP; Harrison CN
Expert Opin Drug Saf; 2016 Sep; 15(9):1185-92. PubMed ID: 27187785
[TBL] [Abstract][Full Text] [Related]
26. Thrombocytopenia in Patients With Myelofibrosis: A Practical Management Guide.
Tremblay D; Baine I; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):e1067-e1074. PubMed ID: 36117043
[TBL] [Abstract][Full Text] [Related]
27. Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden.
Tremblay D; Mesa R; Scott B; Buckley S; Roman-Torres K; Verstovsek S; Mascarenhas J
Blood Adv; 2020 Dec; 4(23):5929-5935. PubMed ID: 33275766
[TBL] [Abstract][Full Text] [Related]
28. Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices.
Tefferi A; Pardanani A; Gangat N
Am J Hematol; 2024 Feb; 99(2):300-308. PubMed ID: 38164985
[TBL] [Abstract][Full Text] [Related]
29. Clinical potential of pacritinib in the treatment of myelofibrosis.
Duenas-Perez AB; Mead AJ
Ther Adv Hematol; 2015 Aug; 6(4):186-201. PubMed ID: 26288713
[TBL] [Abstract][Full Text] [Related]
30. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Al-Ali HK; Griesshammer M; Foltz L; Palumbo GA; Martino B; Palandri F; Liberati AM; le Coutre P; García-Hernández C; Zaritskey A; Tavares R; Gupta V; Raanani P; Giraldo P; Hänel M; Damiani D; Sacha T; Bouard C; Paley C; Tiwari R; Mannelli F; Vannucchi AM
Br J Haematol; 2020 Jun; 189(5):888-903. PubMed ID: 32017044
[TBL] [Abstract][Full Text] [Related]
31. Novel strategies for challenging scenarios encountered in managing myelofibrosis.
Bose P; Mesa RA
Leuk Lymphoma; 2022 Apr; 63(4):774-788. PubMed ID: 34775887
[TBL] [Abstract][Full Text] [Related]
32. First Approval of Pacritinib as a Selective Janus Associated Kinase-2 Inhibitor for the Treatment of Patients with Myelofibrosis.
De SK
Anticancer Agents Med Chem; 2023; 23(12):1355-1360. PubMed ID: 36959157
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.
Sureau L; Orvain C; Ianotto JC; Ugo V; Kiladjian JJ; Luque Paz D; Riou J
Blood Cancer J; 2021 Jul; 11(7):135. PubMed ID: 34315858
[TBL] [Abstract][Full Text] [Related]
34. Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naïve and exposed patients with myelofibrosis.
England JT; Gupta V
Expert Opin Pharmacother; 2022 Oct; 23(15):1677-1686. PubMed ID: 36252265
[TBL] [Abstract][Full Text] [Related]
35. Recent progress of JAK inhibitors for hematological disorders.
Kirito K
Immunol Med; 2023 Sep; 46(3):131-142. PubMed ID: 36305377
[TBL] [Abstract][Full Text] [Related]
36. Myelofibrosis: an update on drug therapy in 2016.
Bose P; Verstovsek S
Expert Opin Pharmacother; 2016 Dec; 17(18):2375-2389. PubMed ID: 27774820
[TBL] [Abstract][Full Text] [Related]
37. Management of myelofibrosis after ruxolitinib failure.
Harrison CN; Schaap N; Mesa RA
Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
[TBL] [Abstract][Full Text] [Related]
38. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
Griesshammer M; Sadjadian P
Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
[TBL] [Abstract][Full Text] [Related]
39. The role of pacritinib in the management of myelofibrosis.
Duong VH; Komrokji RS
Expert Rev Hematol; 2014 Jun; 7(3):325-32. PubMed ID: 24746271
[TBL] [Abstract][Full Text] [Related]
40. How many JAK inhibitors in myelofibrosis?
Ferreira BV; Harrison C
Best Pract Res Clin Haematol; 2014 Jun; 27(2):187-95. PubMed ID: 25189729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]